The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model
Abstract
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by a CAG trinucleotide expansion in exon 1 of the Huntingtin (Htt) gene. We show herein that in an HD transgenic mouse model (R6/2), daily administration of CGS21680 (CGS), an A 2A adenosine receptor (A 2A‐R)‐selective agonist, delayed the progressive deterioration of motor performance and prevented a reduction in brain weight. 3D‐µMRI analysis revealed that CGS reversed the enlarged ventricle‐to‐brain ratio of R6/2 mice, with particular improvements in the left and right ventricles. 1 H‐MRS showed that CGS significantly reduced the increased choline levels in the striatum. Immunohistochemical analyses further demonstrated that CGS reduced the size of ubiquitin‐positive neuronal intranuclear inclusions (NIIs) in the striatum of R6/2 mice and ameliorated mutant Htt aggregation in a striatal progenitor cell line overexpressing mutant Htt with expanded polyQ. Moreover, chronic CGS treatment normalized the elevated blood glucose levels and reduced the overactivation of a major metabolic sensor [5′AMP‐activated protein kinase (AMPK)] in the striatum of R6/2 mice. Since AMPK is a master switch for energy metabolism, modulation of energy dysfunction caused by the mutant Htt might contribute to the beneficial effects of CGS. Collectively, CGS is a potential drug candidate for the treatment of HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979 · cited 2×
“To date, the molecular mechanism underlying the toxicity caused by mutant Htt with expanded polyglutamine (polyQ) remains controversial (Martindale et al. 1998; Arrasate et al. 2004).”
BackgroundNeuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522
Cha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504
Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428 · cited 7×
“…in both HD patients and in R6/2 mice (Podolsky et al. 1972), and because suppressed hyperglycemia has been associated with improvement in neurological deficits of HD (Duan et al. 2003), we performed experiments to determine whether chronic CGS treatment normalized the usage of glucose in R6/2 mice.”
BackgroundMethodInfluentialWinder, W. W., Wilson, H. A., Hardie, D. G., Rasmussen, B. B., Hutber, C. A., Call, G. B., Clayton, R. D., Conley, L. M., Yoon, S., & Zhou, B. (1997) · Journal of Applied Physiology · doi:10.1152/jappl.1997.82.1.219 · Cited by 237
Hansson, O., Petersén, Å., Leist, M., Nicotera, P., Castilho, R. F., & Brundin, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8727 · Cited by 228 · cited 1×
“For example, R6/2 mice are resistant (or less sensitive) to toxicity caused by QA, kainic acid, and 3NP (Hansson et al. 1999; Hickey and Morton 2000; Morton and Leavens 2000).”
BackgroundHong, Y. H., Varanasi, U. S., Yang, W., & Leff, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304112200 · Cited by 220 · cited 1×
“…metabolic enzymes (e.g. acetyl-CoA carboxylase) and reducing ATP consumption upon stress (Winder et al. 1997), AMPK also phosphorylates a wide variety of proteins involving other cellular functions such as gene transcription and secretion (Hong et al. 2003; Lee et al. 2003; Tsuboi et al. 2003).”
BackgroundLai, H.-L., Yang, T.-H., Messing, R. O., Ching, Y.-H., Lin, S.-C., & Chern, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.8.4970 · Cited by 129
Self-citation
Cited by
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
AMP-activated protein kinase: new regulation, new roles?
Carling, D., Thornton, C., Woods, A., & Sanders, M. J. (2012) · Biochemical Journal · doi:10.1042/bj20120546 · Cited by 379
Jiang, M., Wang, J., Fu, J., Du, L., Jeong, H., West, T., Xiang, L., Peng, Q., Hou, Z., Cai, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2558 · Cited by 345
The corticostriatal pathway in Huntington's disease
CEPEDA, C., WU, N., ANDRE, V, CUMMINGS, D., & LEVINE, M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.001 · Cited by 310
Astrocyte molecular signatures in Huntington’s disease
Diaz-Castro, B., Gangwani, M. R., Yu, X., Coppola, G., & Khakh, B. S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8546 · Cited by 255
Metadata
- Authors
- Chou, S., Lee, Y., Chen, H., Chiang, M., Lai, H., Chang, H., Wu, Y., Sun, C., Chien, C., Lin, Y., Wang, S., Tung, Y., Chang, C., & Chern, Y.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2005-03-02
- Volume
- 93
- Issue
- 2
- Pages
- 310-320
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1579287598
- Cited by
- 173
- References
- 9
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.